A Digital Publication for the Practicing Medical Specialist, Industry Executive and Investor
The financing will support a substantial production capacity increase for the unique MIMIX™ hydrophilic biomaterial vascular access devices developed by AVI, which are designed to evade the foreign body reaction by mimicking the human body’s natural chemistry, as well as further research into the potential for MIMIX to lower catheter infection rates, and expansion of AVI’s product portfolio notes Access Vascular.
Neteera raised the first $13 million in April 2023 in a round led by Aescuvest, which led this extension as well. Foxconn Technology joined.
Sigrid Therapeutics notes the funds will be instrumental in accelerating the commercialisation of SiPore® across diverse markets, including medical devices, food supplements, veterinary, and oral health.
Palatin Technologies is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential.
Nine months after the start of shipments, Cionic Neural Sleeve licensed nearly nationwide with more than 200,000 hours of customer use, transforming the lives of those with mobility impairments.The company expands the board with the addition of Whitney Casey, Venture Partner at L Catterton.
Akura Medical reports the funds will be used to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities.